慢性淋巴细胞白血病患者的COVID-19严重程度与死亡率:ERIC与CLL Campus联合研究
该回顾性国际多中心研究纳入190例确诊COVID-19的慢性淋巴细胞白血病(CLL)患者,发现79%为重症COVID-19,重症与年龄≥65岁相关(比值比3.72 [95%CI 1.79-7.71]);重症患者中36.4%死亡,轻症仅2.6%;年龄和合并症未影响死亡率。
要点
- CLL患者COVID-19重症率达79%,重症与年龄≥65岁相关(OR 3.72 [95%CI 1.79-7.71])。
- 重症COVID-19患者中仅39.7%正在或近期(≤12个月)接受CLL治疗,轻症患者中为76.9%。
- 接受伊布替尼治疗的患者重症COVID-19住院率低于其他方案或未治疗者(p < 0.05)。
核心结论
- CLL患者中COVID-19严重程度随年龄增长而增加。
- 抗白血病治疗(尤其是BTK抑制剂)似乎具有保护作用。
- 年龄和合并症未影响死亡率,提示CLL和免疫缺陷发挥重要作用。
研究设计与样本
- 回顾性国际多中心研究,纳入2020年3月28日至2020年5月22日期间确诊COVID-19的190例CLL患者。
主要发现
- 190例患者中151例(79%)表现为重症COVID-19(需要吸氧和/或入住重症监护室)。
- 重症COVID-19与更年长(≥65岁)相关,比值比3.72(95%CI 1.79-7.71)。
- 重症COVID-19患者中60例(39.7%)正在或近期(≤12个月)接受CLL治疗,轻症患者中为30/39例(76.9%)。
- 接受伊布替尼治疗的患者重症COVID-19住院率低于其他方案或未治疗者(p < 0.05)。
- 151例重症患者中55例(36.4%)死亡,轻症患者中仅1/38例(2.6%)死亡;年龄和合并症未影响死亡率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
引用
- Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020. PMID: 32647324. doi:10.1038/s41375-020-0959-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。